To assess cardiac safety in COVID-19 patients treated with the combination of Hydroxychloroquine and Azithromycin using arrhythmia risk management plan. We retrospectively examined arrhythmia safety of treatment with Hydroxychloroquine and Azithromycin in the setting of pre-defined arrhythmia risk management plan. The data was analyzed using R statistical package version 4.0.0. A two-tailed p-value<0.05 was considered significant. 81 patients were included from March 23rd to May 10th 2020. The median age was 59 years, 58.0% were female. The majority of the study population (82.7%) had comorbidities, 98.8% had radiological signs of pneumonia. Fourteen patients (17.3%) experienced QTc ≥ 480 ms and 16 patients (19.8%) had an increase of QTc ≥ 60 ms. Seven patients (8.6%) had QTc prolongation of ≥ 500 ms. The treatment was discontinued in 4 patients (4.9%). None of the patients developed ventricular tachycardia. The risk factors significantly associated with QTc ≥ 500 ms were hypokalemia (p = 0.032) and use of diuretics during the treatment (p = 0.020). Three patients (3.7%) died, the cause of death was bacterial superinfection with septic shock in two patients, and disseminated intravascular coagulation with multiple organ failure in one patient. None of these deaths were associated with cardiac arrhythmias. We recorded a low incidence of QTc prolongation ≥ 500 ms and no ventricular tachycardia events in COVID-19 patients treated with Hydroxychloroquine and Azithromycin using cardiac arrhythmia risk management plan.
1 January 2026 in IEEE Transactions on Biomedical Engineering
Background: A wrist-worn wearable device for acquiring limb and chest ECG leads (wECG) may constitute a promising approach to detection of acute myocardial infarction (AMI). However, it remains to be demonstrated whether the information conveyed by the wECG is sufficient for AMI detection. Objective: To explore explainable machine learning models for detecting AMI using the wECG. Methods: Two types of machine learning models are explored: a convolutional neural network (CNN) using the raw ECG as input and a gradient-boosting decision tree (GBDT) using clinically informative features. 123 participants were included, divided into patients with AMI, patients with other cardiovascular diseases, and healthy individuals. A wrist-worn device equipped with three biopotential electrodes was used to acquire two ECG leads with a single touch: limb lead I and another lead involving a specific body site, i.e., either the V3 or V5 electrode positions, or the abdomen. Results: The best performance on the test dataset is obtained using models that incorporate all four leads. The CNN model performs slightly better than the GBDT model, with a sensitivity of 0.77 and specificity of 0.75 compared to 0.77 and 0.72, respectively. When distinguishing between AMI and healthy participants, the specificity increases to 0.94 for the CNN model and 0.90 for the GBDT model. Feature importance analysis shows that the GBDT model primarily relies on the J point, while the CNN model primarily relies on the QRS complex. Conclusions: wECG-based AMI detection shows considerable promise in out-of-hospital settings. However, caution is needed as CNN explanations rarely agree with the ECG intervals typically analyzed in clinical practice.
25 June 2025 in Journal of Interventional Cardiac Electrophysiology
Robotic magnetic navigation (RMN) has demonstrated clinical utility in treating arrhythmia patients by providing direct distal-tip control of an ablation catheter, enhancing catheter precision, safety, and stability with an atraumatic catheter design. We aimed to assess the first in-human efficacy and safety of the new RMN-guided MAGiCTM radiofrequency ablation catheter. This prospective, multicenter single-arm, unblinded study enrolled 67 patients with arrhythmias that met EHRA guidelines for catheter ablation. All patients were treated for their index arrhythmia with the MAGiC RMN catheter. All other devices used in the procedures were approved for treatment including a RMN System (Genesis/Niobe®) used to navigate the MAGiC catheter. Acute procedural success and adverse events were assessed for all patients through discharge from the hospital in the days following the procedure. Sixty-seven patients were treated as follows: 25 cases of atrioventricular nodal reentrant tachycardia, 19 of premature ventricular contractions, 8 of Wolf-Parkinson-White (WPW) syndrome, 8 of atrial fibrillation, 3 of atrial flutter, and 4 of ventricular tachycardia. Acute procedural success was 94%. There was one cardiac tamponade due to perforation of the right ventricular outflow tract during ablation. Otherwise, no adverse events were observed. The results of this study demonstrate good acute efficacy and safety of the MAGiC RMN ablation catheter independent of underlying arrhythmias. Contact force and stability with MAGiC seem improved compared to previous catheters available with RMN, and therefore radiofrequency energy delivery needs careful attention, especially in thin areas of the myocardium. Additional long-term data are needed.